NICE Issues Final Guidance In Support of Opdivo

NICE has published the final guidance recommending use of Bristol Myers Squibb’s Opdivo within its marketing authorization, as an option for previously treated advanced renal cell carcinoma (RCC) in adults.

Clinical trials have shown that patients treated with the drug after their previous therapy was no longer effective lived for an average of 5.4 months longer than those who received standard targeted therapy.

In three months, eligible patients will be able to get routine access to Opdivo.